Benzinga

Benzinga

Benzinga

martes, agosto 25

Merck & Co Inc

MRKNYSE
Trade with Public
Trade with Public
$156.45
5.793.84%
al cierre: Aug 25, 5:00 PM EST
$156.78
0.330.21%
After hour: 7:24 PM EST
PRO
¿Por qué se mueve?:Merck shares are trading higher after Argus Research and Wolfe Research rai...
Panorámica generalNoticiasPrevisión de beneficiosEventosPrecios objetivoFinanzasSentimientoPropiedadDividendosCompararOpcionesInforme de acciones

Merck & Co Financials

Merck & Co (MRK) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

Stock Market Today: Dow Jones, S&P 500 Futures Fall as Trump Launches 'Operation Economic Fury' on Iran— BULL, WMT, MRK Stock in Focus

U.S. stock futures were lower on Thursday, as the Dow Jones, S&P 500 and Nasdaq 100 indices fell, following Wednesday’s higher close. President Donald Trump announced a harsh economic offensive against Iran
Rishabh Mishra

Moderna Doubles, Gold Rallies To $4,500 As Dollar Sinks: Stock Market Today

Treasury's expanded long-bond buybacks knocked yields off 20-month highs and sank the dollar, as gold soars.
Piero Cingari

Why Merck Just Slashed Its Profit Outlook By Nearly 50%

Merck cuts FY2026 adjusted EPS outlook nearly in half to $2.66-$2.76, citing $2.43/share in charges from its Terns acquisition.
Vandana Singh

PRO
Merck & Co Lowers FY2026 Adj EPS Guidance from $5.04-$5.16 to $2.66-$2.76 vs $2.76 Est; Raises FY2026 Sales Guidance from $65.800B-$67.000B to $66.300B-$67.300B vs $66.802B Est

Merck & Co (NYSE:MRK) lowers FY2026 Adj EPS guidance from $5.04-$5.16 to $2.66-$2.76 vs $2.76 analyst estimate. Raises FY2026 sales outlook from $65.800 billion-$67.000 billion to $66.300 billion-$67.300 billion vs
Benzinga Newsdesk

PRO
Merck & Co Q2 Adj. EPS $(0.13) Beats $(0.27) Estimate, Sales $16.607B Beat $16.356B Estimate

Merck & Co (NYSE:MRK) reported quarterly losses of $(0.13) per share which beat the analyst consensus estimate of $(0.27) by 51.85 percent. This is a 106.1 percent decrease over earnings of $2.13 per share from the
Benzinga Newsdesk

Tempus AI's Big Pharma AI Partnerships Are Getting Bigger And Stickier

Tempus AI (TEM) Q1 results: Revenue up 36.1% to $348.1M, beating estimates. TEM raises 2026 outlook amid strong AI & diagnostic demand.
Lekha Gupta

Datos y APIs: APIs de Benzinga · API de noticias de acciones · API de calificaciones de analistas · API de logotipos de empresas

Benzinga

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

© 2026 Benzinga | All Rights Reserved